Using this model, scientists can get a better understanding of the functional, structural and molecular changes associated with clinical ischemic heart disease as well as investigate the cardio-protection of potential drug therapies
Saint Paul, MN (PRWEB) June 16, 2010
MD Biosciences, a Preclinical Contract Research Organization (CRO), offers in vivo models for the study of myocardial infarct (MI). The occlusion-induced myocardial infarct model is a well-known technique for investigating the cardio-protection of a drug therapy in the event of ischemia/reperfusion injury. The advantage of the model is the ability to study the functional relevance of a drug treatment on the heart following direct coronary flow and the mechanisms by which the drug promotes myocardial protection.
Occlusion-induced Ischemia Reperfusion Injury
Occlusion of the left coronary artery is performed to mimic myocardial infarction in humans that results from occlusion of arteriosclerotic plaques of coronary arteries. Using this model, scientists can get a better understanding of the functional, structural and molecular changes associated with clinical ischemic heart disease as well as investigate the cardio-protection of potential drug therapies. Following the 45 minutes of LAD occlusion, the LAD is opened and coronary blood flow is allowed. Therefore, any IV dosed drug will reach the heart tissue and the infarct area immediately.
The figure here shows histology on four heart tissue samples from a vehicle treated group (A-B) and an active compound group (C-D) in the occlusion-induced ischemia reperfusion injury model. Occlusion duration was 45 minutes and reperfusion was over 48 hours. Slides A-D: transverse section of the heart at 0.5x magnification. Slides E-H: 4x magnification of slides A-D showing the scarred myocardium.
Study design can be customized to determine the duration of reperfusion following a 45-minute occlusion period. Readouts of the occlusion-induced ischemia-reperfusion injury model include histology of the heart as well as CPK and Troponin levels, which are relevant blood markers of myocardial infarction. For more information and data on the occlusion-induced IR injury model, download the Whitepaper 'Myocardial Infarct models for evaluating the myocardial protection or potential drug therapies' at http://www.mdbiosciences.com.
About MD Biosciences
MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.
The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.
# # #